# Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)

> **NCT06306300** · PHASE4 · UNKNOWN · sponsor: **Oswaldo Cruz Foundation** · enrollment: 30000 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Specialist - Epclusa 400Mg-100Mg Tablet
- **DRUG:** Non- specialist - Epclusa 400Mg-100Mg Tablet

## Key facts

- **NCT ID:** NCT06306300
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30000 (ESTIMATED)
- **Last updated:** 2024-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06306300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06306300, "Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06306300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*